Baricitinib (LY3009104)

Catalog No. A11329

Baricitinib，也称为INCB028050或LY3009104，是一种选择性口服可生物利用的JAK1/JAK2抑制剂，对JAK1（5.9 nM）和JAK2（5.7 nM）具有纳摩尔浓度。

Product Citations

Yuki Sasaki, .et al. Blockade of the CXCR3/CXCL10 axis ameliorates inflammation caused by immunoproteasome dysfunction, JCI Insight, 2022, Apr 8;7(7) PMID: 35393946
Yutian Lei, .et al. A multicenter blinded preclinical randomized controlled trial on Jak1/2 inhibition in MRL/MpJ-Fas lpr mice with proliferative lupus nephritis predicts low effect size, Kidney Int, 2021, Feb 16 PMID: 33607177

Technical details

Catalog Num	A11329
M. Wt	371.4
Formula	C16H17N7O2S
Purity	>98%
Storage	at -20°C 3 years Powder
CAS No.	1187594-09-7
Synonyms	INCB28050, LY3009104
SMILES	CCS(=O)(=O)N1CC(C1)(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3

Biological Activity

Baricitinib，也称为INCB028050或LY3009104，是一种选择性口服可生物利用的JAK1/JAK2抑制剂，对JAK1（5.9 nM）和JAK2（5.7 nM）具有纳摩尔浓度。

Targets

Target	Value
JAK2	IC50: 5.7nM
JAK1	IC50: 5.9nM
TYK2	IC50: 53nM
JAK3	IC50: >400nM
Chk2	IC50: >1μM
c-Met	IC50: >10μM

Solubility *

In vitro (25°C)	DMSO	65 mg/mL (175 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	2% DMSO+30% PEG 300+5% Tween 80+ddH2O	4 mg/mL
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Preparing Stock Solutions

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.1 mM	26.93 mL	134.63 mL	269.25 mL
0.5 mM	5.39 mL	26.93 mL	53.85 mL
1 mM	2.69 mL	13.46 mL	26.93 mL
5 mM	0.54 mL	2.69 mL	5.39 mL

*The above data is based on the productmolecular weight 371.4 . Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.